HBW-Insights-articles_hero

Like other big global OTC players, Bayer Consumer Health is stepping up its investment in digital self-care. In the first part of an exclusive two-part interview, HBW Insight interviews the company's head of R&D and chief scientific officer David Evendon-Challis to dig deeper into the rationale for setting up a new 'precision health' business unit.

There are predictions that precision health will be up to 20% of the consumer health market.
Bayer Consumer Health’s head of R&D and chief scientific officer David Evendon-Challis

Related resources

Biopharma professional on laptop browsing Pink Sheet for global policy and regulatory insights.
MAY 01, 2022
eBook
薬事規制関連支援サービス

Your Keys to Understanding EU Transparency

A collection of Pink Sheet articles covering evolving EU regulations on clinical trial disclosure and transparency

HBW-Insights-articles_resource-card-thumbnail
JUL 04, 2023
Article
商業化支援サービス

Bayer Consumer Health Exec Cites the ‘Huge Potential’ of OTC Digital Therapeutics, AI

Bayer Consumer Health's R&D head/chief scientific officer cites the opportunities in a new generation of OTC digital therapeutics and AI-driven self-care.